Knowledge on the Use of Isotretinoin and Its Side Effects and Awareness towards Saudi FDA-Pregnancy Prevention Program among the Female Acne Patients: A Northern Saudi Study

Ziad Mansour Alshaalan

Division of Dermatology, Department of Internal Medicine, College of Medicine, Jouf University, Sakaka 72388, Saudi Arabia; dr.ziad@ju.edu.sa; Tel.: +966-56600909

Abstract: Background and Objectives: Acne vulgaris is one of the most common dermatological disorders among adolescents and adults in the Kingdom of Saudi Arabia (KSA). Isotretinoin is a cost-effective way of treating severe acne patients compared to other methods used for severe forms of acne management. The present study investigated the knowledge of the use of isotretinoin and its side effects among female acne patients of the reproductive age group who were on isotretinoin. This study also assessed participants' awareness of the Saudi FDA-Pregnancy Prevention Program (SFDA-PPP).

Materials and Methods: The present population-based cross-sectional survey was conducted among 768 participants using a standard and validated Arabic version questionnaire. We have applied logistic regression analysis to determine the predictors for awareness of SFDA-PPP. A Chi-square test was applied to identify the factors associated with knowledge related to isotretinoin.

Results: Regarding the side effects of isotretinoin, participated female acne patients were most commonly aware of dry mouth and lips (84.5%), teratogenicity (68.2%), and headache (44.8%). Nearly 60% of the participants belonged to the low knowledge category. The present study participants' knowledge was significantly associated with education status ($p = 0.007$), occupation ($p = 0.01$), and those participants who were aware of SFDA-PPP ($p = 0.001$). Furthermore, we explored that only 37.5% were aware of the SFDA-PPP program implemented in Saudi Arabia. The awareness of SFDA-PPP was significantly higher among those participants belonging to health sectors (Adjusted OR (95% CI) = 1.39 (1.01–1.92), $p = 0.049$).

Conclusion: The present survey explored inadequate knowledge among reproductive age group female acne patients regarding isotretinoin uses, precautions to be followed, and side effects, especially teratogenic effects. This survey findings suggest that improving female acne patients’ knowledge of isotretinoin through health promotion activities is crucial, especially by giving them precise instructions about the teratogenic effects.

Keywords: isotretinoin; severe acne; teratogenicity; Saudi FDA-PPP; knowledge; side effects

1. Introduction

Acne vulgaris is one of the most common dermatological disorders among adolescents and adults internationally and in the Kingdom of Saudi Arabia (KSA) [1,2]. The prevalence of acne vulgaris during adolescence is higher among males, but during adulthood, it affects females more commonly than males [2,3]. Acne vulgaris can affect the psychosocial life of the affected patients, and this impact is higher among females than males [4,5].

Treatment for acne vulgaris ranges from topical retinoids to systemic antibiotics or combined therapy [6]. Isotretinoin is an oral and only effective medication for the cure or prolonged remission of moderate to severe acne, when recommended as monotherapy, improving skin appearance and health-related quality of life [7]. Some authors in the KSA reported that isotretinoin use among females is high. A recent study by Albadr et al. among female college students reported that 48.2% of them used isotretinoin for their acne treatment [8]. Another recent survey from Jeddah city of KSA stated that 22.7%
of the females (12–60 years of age group) used isotretinoin at least once for their acne management [9]. The commonly reported adverse effects of the isotretinoin are dry mouth, dry eye, pruritis, photosensitivity, and dysglycemia [7,10]. Even though isotretinoin causes many adverse effects, the teratogenicity caused by this medication is the most serious. It is reported that about one-third of infants exposed to in-utero isotretinoin had the risk of teratogenicity [11,12]. There are several congenital malformations reported by previous researchers, mainly craniofacial defects, cardiovascular and neurological malformations, or thymic disorders [12,13].

In the KSA, the Saudi Food and Drug Authority (SFDA) was established to ensure food and drug safety for humans and animals through different rules and regulations [14]. The below table compares the SFDA-PPP of KSA [14], PPP implemented in the United Kingdom [15], and iPLEDGE from the United States of America [16]. Important features among these programs are compared in Table 1.

| Salient Features           | SFDA-PPP (KSA)                                                                 | iPLEDGE (USA)                                                                 | PPP (UK)                                                                 |
|----------------------------|-------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------|
| Year implemented           | 2013                                                                          | 2006                                                                         | 1988                                                                   |
| Prescribers                | Prescribed by experts (dermatologists and family physicians) registered with Saudi commission for health specialties | Only iPLEDGE enrolled and activated healthcare providers can prescribe isotretinoin. | Can only be prescribed within a team led by a consultant dermatologist |
| Contraception advice       | The physician should ensure that the patient has two effective contraception methods; importantly, they should include a barrier device as a second method. | The physician should ensure that the patient has two methods effective contraception methods. Importantly they should include a barrier device as a second method. | Contraception should commence 1 month before treatment and progress until the patient is free from retinoid. |
| Pregnancy test             | Treatment is subject to pregnancy tests.                                       | A pregnancy test must be taken before a patient is subjected to oral isotretinoin. | All pregnancy tests that fall under 25 mIU/mL sensitivity should be recorded 3 days before the prescription. |
| Prescription duration from a single visit | Limited to 4 weeks. Monthly renewal (if required).                           | Limited to 4 weeks. Monthly renewal (if required).                           | Limited to 4 weeks. Monthly renewal (if required)                       |
| In the event pregnancy happened | Treatment is stopped immediately, and the patient should be referred to a specialist in teratogenicity for advice. | Treatment must be stopped immediately if the woman being treated with oral Isotretinoin is pregnant. | Treatment should be excluded for pregnant women.                      |
| Distribution system        | A distribution control system is established to limit the misuse.             | Available only through a restricted distribution program.                    | A restricted distribution is established and monitored. Isotretinoin to be given within 7 days of issuance of prescription. |

The SFDA also specified that oral isotretinoin is subjected to SFDA-Pregnancy Prevention Program (SFDA-PPP). Hence, physicians, pharmacists, and acne patients must be familiar with isotretinoin’s teratogenic effects [17].

Continuous assessment of female acne patients’ awareness regarding isotretinoin uses and its adverse effect, including teratogenicity, is critical for SFDA to plan necessary training and health education sessions for all parties (patients, prescribers, and pharmacists). However, we lack data in the northern region of the KSA. Hence, this study was executed to determine the knowledge of the use of isotretinoin and its side effects among female acne patients of
the reproductive age group. This study also assessed awareness of SFDA-PPP and associated factors among them.

2. Materials and Methods

2.1. Participants and Setting

The present population-based cross-sectional study was conducted from March 2022 to August 2022 among female acne patients of reproductive age group attending dermatology clinics and outreach clinics conducted at different public places such as malls, masjids, and parks.

2.2. Sample Size

We have concluded the required minimum number of female acne patients using the WHO sample size calculator with the infinite population. To calculate the minimum required sample size, we have taken the confidence interval of 95%, population proportion of 50%, the margin of error of 5%, and the power of the study as 80%. Furthermore, we have taken design effect two. Applying all the values, the estimated sample size was 768 for the current survey.

2.3. Sampling Method

The survey team collected data using a consecutive sampling method. In this method, the data collectors invited the female participants for preliminary screening for the eligibility to be included in the present survey. The study included all acne patients of reproductive age group (aged 18 to 49 years) who were on isotretinoin at the time of data collection and have taken isotretinoin during the past five years (minimum of one treatment course). We excluded the participants who were not willing to participate. The age limit was considered based on the World Health Organization (WHO) classification of the child-bearing age and minimum marriage age limits for girls in the KSA.

2.4. Data Collection Procedure

This population-based study questionnaire was distributed to the female acne patients of reproductive age group after ethical clearance from the concerned authorities (Ethics committee, Qurrayat Health Affairs, Qurayyat, Saudi Arabia, Project no: 138, 2022). The data collectors adhered to all COVID-19 prevention strategies instituted by the ministry of health during the study period. Initially, the survey team briefed the study’s objectives to the eligible participants, and informed consent was obtained from them before proceeding with the survey. The acne patients were requested to fill in the google form, the standard and validated tool prepared by the research team based on the existing pieces of literature. The data collection proforma was designed by experts, including a dermatologist, public health specialist, and obstetrician. Hence, we ensured the designed questionnaire represents and covers all facets of the present study’s objectives (face and content validity). We have prepared this proforma from the available works of literature [8,9,18]. The prepared proforma is translated to Arabic by experts in bilingual (English–Arabic). Finally, the Arabic version is back-translated to English by the bilingual non-medical people to that the original meaning is retained. The survey team implemented a pilot study with thirty acne patients on isotretinoin. All patients ensured the constructed questionnaire was clear and easy to understand. The data collection proforma consisted of three parts. Part 1 inquired about the socio-demographic and background details of the acne patients on isotretinoin. The second part inquired about the participants’ knowledge related to the use and side effects of isotretinoin. In the knowledge section, acne patients were given multiple-choice questions to answer. We have given one mark for the correct answer and zero for the wrong answer. After computing all the correct answers of all items, we categorized them into low ($\leq$ mean knowledge score) and high ($>$ mean knowledge score). The final part consisted of acne patients’ awareness of the SFDA-PPP program. The research team performed a sub-analysis among the married females and participants who had planned to marry within one month.
The present study team assessed the importance of pregnancy tests and contraceptives, as per the SFDA-PPP guidelines received from the care providers.

2.5. Statistical Analysis

The completed Excel sheet was downloaded, recorded, and analyzed using the statistical package for social sciences (SPSS, Version 24.0). The descriptive statistics of the study are presented as frequency (n), proportion (%) for the qualitative variables, and mean and SD for the quantitative variables. We applied the chi-square test to compare the factors associated with the knowledge of isotretinoin and its side effects. Finally, we used binomial logistic regression analysis to find the predictors for the awareness related to SFDA-PPP. All statistical tests applied in this study were two-tailed, and a p-value less than 0.05 was fixed as statistically significant.

3. Results

In the present survey, 768 female acne patients participated. Of the participating acne patients, nearly three-fourths (72.3%) studied above high school, the majority (62.9%) of them were single, and 11.0% of the single females had their marriage plans in six months. Among the respondents, 38.8% belong to health sectors, 62.2% live in urban regions, 32.3% had taken isotretinoin during the past year, and 92.7% received isotretinoin with a doctor’s prescription. Regarding SFDA-PPP, only 37.5% were aware of it (Table 2).

Table 3 shows the respondents’ knowledge of use, precautions to be followed while on isotretinoin, and side effects of isotretinoin. Of the responding females, 35.5% were aware of the indication of isotretinoin, 44.9% recognized that patients on isotretinoin must take plenty of water, and only 36.7% answered correctly on blood donation. The most commonly recognized side effects were dry mouth, nose, and lips (84.5%), followed by teratogenicity (68.2%) and headache (44.8%).

After computing all the correct answers of all items, we categorized them into low (≤mean knowledge score) and high (>mean knowledge score). The participants’ knowledge towards isotretinoin was significantly associated with education status (p = 0.007), occupation (p = 0.01), their current sector (p = 0.018), and those participants who were aware of SFDA-PPP (p = 0.001) (Table 4).

The research team performed a sub-analysis among the married females and participants who had a plan to marry within one month. Among them (308 participants), we investigated the importance of pregnancy tests and contraceptives, as per the SFDA-PPP guidelines received from the care providers (Figures 1 and 2). Of the 308 participants’ sub-analysis, 63.6% and 48.7% received information on the importance of performing pregnancy tests before and during treatment. In contrast, only 39.9% of them received instructions related to pregnancy tests within five weeks. Regarding the use of contraceptive methods, only less than half of the participants received instructions related to the importance of contraceptive usage before starting treatment (43.8%), during treatment (40.9%), and four weeks after stopping treatment (41.2%).

Table 2. Background characteristics of the acne patients who participated in the study (n = 768).

| Background Characteristics     | Frequency | Percentage |
|-------------------------------|-----------|------------|
| Age: Mean (SD)                | 30.17 (7.52) |            |
| ≤30 Years                     | 377       | 49.1       |
| >30 Years                     | 391       | 50.9       |
| Education status              |           |            |
| Up to high school             | 213       | 27.7       |
| Above high school             | 555       | 72.3       |
Table 2. Cont.

| Background Characteristics          | Frequency | Percentage |
|-------------------------------------|-----------|------------|
| Marital status                      |           |            |
| Single                              | 483       | 62.9       |
| Married                             | 251       | 32.7       |
| Divorced/Widowed                    | 34        | 4.4        |
| Marriage plan within one month *    |           |            |
| No                                  | 371       | 71.7       |
| Yes                                 | 57        | 11         |
| Not sure                            | 89        | 17.2       |
| Occupation                          |           |            |
| Government                          | 208       | 21         |
| Private sector/business             | 130       | 16.9       |
| Unemployed                          | 161       | 27.1       |
| Student                             | 269       | 35         |
| Occupation/Education sector         |           |            |
| Non-Health                          | 470       | 61.2       |
| Health                              | 298       | 38.8       |
| Living place                        |           |            |
| Urban                               | 478       | 62.2       |
| Rural                               | 290       | 37.8       |
| Isotretinoin use                    |           |            |
| Past one year                       | 248       | 32.3       |
| Before one year                     | 520       | 67.7       |
| Have you taken isotretinoin          |           |            |
| with a doctor’s prescription?       |           |            |
| Yes                                 | 712       | 92.7       |
| No                                  | 56        | 7.3        |
| Awareness of SFDA-PPP               |           |            |
| Yes                                 | 288       | 37.5       |
| No                                  | 480       | 62.5       |

* Not applicable for married participants.

Table 3. Participants’ knowledge of the use, precautions, and side effects of isotretinoin (n = 768).

| Items                                                      | Correct Answer n (%) | Wrong Answer n (%) |
|------------------------------------------------------------|----------------------|--------------------|
| Type of acne patients prescribed with isotretinoin          | 273 (35.5)           | 495 (64.5)         |
| Patients who are on isotretinoin must take plenty of water | 345 (44.9)           | 423 (55.1)         |
| Maximum daily dosage of isotretinoin                       | 379 (49.3)           | 389 (50.7)         |
| Patients can donate blood while on isotretinoin treatment  | 486 (63.3)           | 282 (36.7)         |
| Patients can take isotretinoin for more than six months without stopping | 561 (73.0)           | 207 (27.0)         |
| Side effects—Dry mouth, nose, and lips                     | 649 (84.5)           | 119 (15.5)         |
| Side effects—Skin rashes                                   | 300 (39.1)           | 468 (60.9)         |
| Side effects—Headache                                      | 344 (44.8)           | 424 (55.2)         |
| Side effects—Dysglycemia                                   | 196 (25.5)           | 572 (74.5)         |
| Side effects—Teratogenicity                                | 524 (68.2)           | 244 (31.8)         |
| Mean ± SD of the total score                               | 5.03 ± 1.76          |
Table 4. Association between background characteristics and knowledge category (Statistical test applied—Chi-Square test).

| Background Characteristics                  | Low      | High     | p-Value |
|---------------------------------------------|----------|----------|---------|
| Age                                         |          |          |         |
| ≤30 Years                                   | 240 (63.7) | 137 (36.3) | 0.074   |
| >30 Years                                   | 228 (58.3) | 163 (41.7) |         |
| Education status                            |          |          |         |
| Up to high school                           | 146 (68.5) | 67 (31.5)  | 0.007 * |
| Above high school                           | 322 (58.0) | 233 (42.0) |         |
| Marital status                              |          |          |         |
| Single                                      | 285 (59.0) | 198 (41.0) |         |
| Married                                     | 160 (63.7) | 91 (36.3)  |         |
| Divorced/Widowed                            | 23 (67.6)  | 11 (32.4)  |         |
| Occupation                                  |          |          |         |
| Government                                  | 111 (53.4) | 97 (46.6)  |         |
| Private sector/business                     | 71 (54.6)  | 59 (45.4)  |         |
| Unemployed                                  | 113 (70.2) | 48 (29.8)  |         |
| Student                                     | 166 (61.7) | 103 (38.3) |         |
| Occupation/Education sector                 |          |          |         |
| Non-Health                                  | 302 (64.3) | 168 (35.7) | 0.018 * |
| Health                                      | 166 (55.7) | 132 (44.3) |         |
| Living place                                |          |          |         |
| Urban                                       | 287 (60.0) | 191 (40.0) |         |
| Rural                                       | 181 (62.4) | 109 (37.6) |         |
| Isotretinoin use                            |          |          |         |
| Past one year                               | 327 (62.9) | 193 (37.1) | 0.109   |
| Before one year                             | 141 (56.9) | 107 (43.1) |         |
| Awareness SFDA-PPP                          |          |          |         |
| Yes                                         | 330 (68.8) | 150 (31.3) | 0.001 * |
| No                                          | 138 (47.9)  | 150 (52.1) |         |

* Significant value at p value < 0.05

Figure 1. Instructions received about importance of performing pregnancy test (n = 308).
The present study investigated female acne patients’ awareness of SFDA-PPP. Of the 768 respondents, only 288 (37.5%) were aware of the SFDA-PPP program implemented in the KSA. Using SPSS, the predictors of SFDA-PPP were identified. Firstly, we executed a univariate statistical method (binomial logistic regression) followed by multivariate analysis. The multivariate analysis revealed that awareness of SFDA-PPP was significantly higher among those participants belonging to health sectors (AOR (95% CI) = 1.39 (1.01–1.92), \( p = 0.049 \)), and those who were on isotretinoin in past one year (AOR (95% CI) = 1.55 (1.13–2.14), \( p = 0.007 \)). In contrast, awareness on SFDA-PPP were significantly lower among unemployed participants (AOR (95% CI) = 0.65 (0.41–0.97), \( p = 0.029 \)) and those who work in private sectors (AOR (95% CI) = 0.53 (0.31–0.67), \( p = 0.026 \)) (Tables 5 and 6).

Table 5. Factors associated with the awareness of SFDA-PPP: Univariate analysis (Statistical test applied—binomial logistic regression).

| Background Characteristics | Total | No (480) | Yes (280) | Unadjusted Odds Ratio (95% CI of OR)* | p-Value ** |
|----------------------------|-------|----------|-----------|------------------------------------|-----------|
| **Age**                    |       |          |           |                                    |           |
| \( \leq 30 \text{ Years} \) | 377   | 231      | 146       | Ref.                              | 0.491     |
| >30 Years                  | 391   | 249      | 142       | 0.90 (0.67–1.21)                   | 0.491     |
| **Education status**       |       |          |           |                                    |           |
| Up to high school          | 213   | 142      | 71        | Ref.                              | 0.14      |
| Above high school          | 555   | 338      | 217       | 1.28 (0.92–1.79)                   | 0.14      |
| **Marital status**         |       |          |           |                                    |           |
| Single                     | 517   | 314      | 203       | Ref.                              | 0.147     |
| Married                    | 251   | 166      | 85        | 0.79 (0.58–1.09)                   | 0.147     |
| **Occupation**             |       |          |           |                                    |           |
| Government                 | 208   | 119      | 89        | Ref.                              |           |
| Private sector/business    | 130   | 88       | 42        | 1.57 (0.99–2.48)                   | 0.054     |
| Unemployed                 | 161   | 105      | 56        | 1.40 (0.92–2.15)                   | 0.118     |
| Student                    | 269   | 168      | 101       | 1.24 (0.86–1.80)                   | 0.247     |
| **Occupation/Education sector** | | | | | |
| Non-Health                 | 470   | 307      | 163       | Ref.                              |           |
| Health                      | 298   | 173      | 125       | 1.36 (1.01–1.83)                   | 0.043 **  |
| **Living place**           |       |          |           |                                    |           |
| Urban                      | 478   | 181      | 297       | Ref.                              |           |
| Rural                      | 290   | 107      | 183       | 0.96 (0.79–1.26)                   | 0.817     |
Table 5. Cont.

| Background Characteristics | Total | Saudi FDA Awareness | Unadjusted Odds Ratio (95% CI of OR) | p-Value ** |
|----------------------------|-------|---------------------|-------------------------------------|------------|
|                            |       | No (480) | Yes (280) |                                  |            |
| Isotretinoin use           |       |           |           |                                  |            |
| Past one year              | 248   | 139       | 109       | Ref.                              |            |
| Before one year            | 520   | 341       | 179       | 1.49 (1.08–2.04)                  | 0.011 **   |

* Binomial logistic regression (enter method): Univariate and unadjusted OR. ** Significant value at 0.05.

Table 6. Factors associated with the awareness about Saudi FDA—Multivariate analysis (Statistical test applied—binomial logistic regression).

| Background Characteristics | Total | Saudi FDA Awareness | Adjusted Odds Ratio (95% CI of AOR) | p-Value ** |
|----------------------------|-------|---------------------|-------------------------------------|------------|
|                            |       | No (480) | Yes (288) |                                  |            |
| Age                        |       |           |           |                                  |            |
| ≤30 Years                  | 377   | 231       | 146       | Ref.                              |            |
| >30 Years                  | 391   | 249       | 142       | 0.76 (0.49–1.25)                  | 0.308      |
| Education status           |       |           |           |                                  |            |
| Up to high school          | 213   | 142       | 71        | Ref.                              |            |
| Above high school          | 555   | 338       | 217       | 1.26 (0.88–1.79)                  | 0.201      |
| Marital status             |       |           |           |                                  |            |
| Single                     | 517   | 314       | 203       | Ref.                              |            |
| Married                    | 251   | 166       | 85        | 0.79 (0.53–1.17)                  | 0.236      |
| Occupation                 |       |           |           |                                  |            |
| Government                 | 208   | 119       | 89        | Ref.                              |            |
| Private sector/business    | 130   | 88        | 42        | 0.53 (0.31–0.67)                  | 0.026 **   |
| Unemployed                 | 161   | 105       | 56        | 0.65 (0.41–0.97)                  | 0.029 **   |
| Student                    | 269   | 168       | 101       | 0.72 (0.45–1.15)                  | 0.173      |
| Occupation/Education sector|       |           |           |                                  |            |
| Non-Health                 | 470   | 307       | 163       | Ref.                              |            |
| Health                     | 298   | 173       | 125       | 1.39 (1.01–1.92)                  | 0.049 **   |
| Living place               |       |           |           |                                  |            |
| Urban                      | 478   | 181       | 297       | Ref.                              |            |
| Rural                      | 290   | 107       | 183       | 0.94 (0.59–1.48)                  | 0.792      |
| Isotretinoin use           |       |           |           |                                  |            |
| Before one year            | 520   | 341       | 179       | Ref.                              |            |
| Past one year              | 248   | 139       | 109       | 1.55 (1.13–2.14)                  | 0.007 **   |

* Binomial logistic regression (enter method): Adjusted variables age, education status, marital status, occupation, current education/occupation section, living place, and isotretinoin use. ** Significant value at 0.05.

4. Discussion

Isotretinoin is a cost-effective way of treating severe acne patients compared to other methods used for severe forms of acne management [19]. However, it has been proven to cause some severe, including teratogenic, side effects and consumers must be aware of those side effects [20,21]. Hence, the present survey, the first in the northern region, assessed knowledge of the use of isotretinoin and its side effects among female acne patients of the reproductive age group.

The present study explored that 92.7% of acne patients obtained isotretinoin with a prescription from the doctor. Even though it is expected that isotretinoin must be dispensed with proper prescription and consent forms, our results align with some recently published studies from the KSA [8,9,22]. This may be related to more than just pharmacist dispense, and this could be due to using isotretinoin prescribed for the siblings, purchased while on travel to other countries, etc. These epidemiological survey findings indicate that the
knowledge of the community pharmacist must be improved to adhere to policy regarding isotretinoin and the need for SFDA-PPP awareness-raising campaigns beyond consumers (acne patients who is on isotretinoin) [23].

The current survey’s female participants recognized dry mouth, nose, and lips (84.5%) as the most common side effects of isotretinoin. Our findings are consistent with previous studies conducted in the KSA and other parts of the world [24–26]. Teratogenicity is one of the severe adverse effects of isotretinoin that female acne patients at reproductive age must be aware of. Nonetheless, our survey found that nearly two-thirds (68.2%) were aware of the teratogenic side effects. The low level of awareness regarding this severe side effect is an alarming phenomenon noted in our survey. These results contrast with another study by Younis NS et al. They reported that a higher proportion (88.9%) of the community participants were aware that teratogenicity is a dangerous side effect associated with isotretinoin use [26]. The possible reasons for this dissimilarity could be the study setting, inclusions, and exclusion of the study participants. Our study included female acne patients of the reproductive age group from the northern KSA. Younis NS et al. assessed public awareness towards isotretinoin from the Eastern province of KSA. Furthermore, these differences across the KSA also support the rationale of our study on the necessity of having region-specific data.

Another interesting finding explored by the present study was related to blood donation. The current population-based survey found that only 63.3% of the respondents knew that patients on isotretinoin should not donate blood during treatment or within 30 days of stopping isotretinoin. A recently published study from Jordan by Jarab AS et al. in 2022 reported a higher proportion of participants aware of not donating blood while on isotretinoin [27]. Another study conducted by Imam SA et al. in 2021 showed that almost half (50.5%) of their study participants did not know that they should not donate blood during the treatment [28].

Patients’ knowledge about the prescribed drugs, risks, benefits, and precautions to follow during treatment is a critical predictor of treatment outcome [29,30]. Our study showed that the participants’ knowledge of isotretinoin uses, and side effects was significantly associated with education status ($p = 0.007$), occupation ($p = 0.01$), and their current working sector ($p = 0.018$). In contrast to our study statement, a study conducted by Jarab AS et al. showed a non-significant association between knowledge of isotretinoin with education and occupation [27]. These contrasting results could be due to respondents’ background characteristics. We have included female acne patients of the reproductive age group, while Jarab AS et al. included both genders in their study. Another published study by Alharbi et al. presented a positive association between gender and some of the side effects of isotretinoin [31].

Some authors in the past explored the awareness of important health-related organizations of the KSA and their activities, including SFDA-PPP [17,32]. However, to the best of our knowledge, the present study is the first one that evaluated the factors associated with awareness of SFDA-PPP. Regarding SFDA-PPP guidelines, the present study found that nearly two-thirds of the married participants and patients who had a plan to marry within a month received information on the importance of performing pregnancy tests before and during treatment. Currently, SFDA-PPP program activities are targeted only at consumers. This could be a possible reason for the present study’s low awareness (37.5%). Interestingly much lower awareness of SFDA-PPP (30.6%) was found by a study in the capital city (Riyadh) of Saudi Arabia [17]. Our study findings are supported by another study by Ibrahim et al. that evaluated SFDA-PPP guidelines received among female acne patients [17].

**Strengths and Limitations**

Our study is the first study that assessed awareness of SFDA-PPP and its predictive factors, and certain patients’ characteristics lead to a lesser understanding of risks in northern region. Secondly, all the participants were informed about the uses, side effects
inadequate knowledge among reproductive age group female acne patients regarding isotretinoin uses, precautions to be followed, and side effects, especially teratogenic effects. Hence, improving female acne patients’ knowledge through health promotion activities is crucial, especially precise instruction about the teratogenic effects of isotretinoin must be given. We found a low-level awareness among the participants towards SFDA-PPP activities. Furthermore, we revealed that nearly one-third of the married participants did not receive SFDA-PPP guidelines on pregnancy tests and contraception methods to be followed. Therefore, awareness-raising campaigns about SFDA-PPP and its activities are to be implemented by the responsible authorities. These campaigns should be targeted to all females of reproductive age group, including acne patients. Finally, the present study aimed to understand the patients’ knowledge and certain patient’s characteristics lead to lesser understanding of risks. The present study’s findings indicate a need for future research that to be conducted among other two stakeholders (pharmacists and doctors) of SFDA-PPP.

**5. Conclusions**

The present survey explored inadequate knowledge among reproductive age group female acne patients regarding isotretinoin uses, precautions to be followed, and side effects, especially teratogenic effects. Hence, improving female acne patients’ knowledge through health promotion activities is crucial, especially precise instruction about the teratogenic effects of isotretinoin must be given. We found a low-level awareness among the participants towards SFDA-PPP activities. Furthermore, we revealed that nearly one-third of the married participants did not receive SFDA-PPP guidelines on pregnancy tests and contraception methods to be followed. Therefore, awareness-raising campaigns about SFDA-PPP and its activities are to be implemented by the responsible authorities. These campaigns should be targeted to all females of reproductive age group, including acne patients. Finally, the present study aimed to understand the patients’ knowledge and certain patient’s characteristics lead to lesser understanding of risks. The present study’s findings indicate a need for future research that to be conducted among other two stakeholders (pharmacists and doctors) of SFDA-PPP.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** The study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics committee, Qurrayat Health Affairs, Saudi Arabia, Project No: 138, 2022.

**Informed Consent Statement:** Informed consent was obtained from all subjects involved in the study.

**Data Availability Statement:** The data presented in this study are available on request from the corresponding author.

**Acknowledgments:** The author wish to thank Afrah Altaymani and Ziyad Muharib N. Alruwaili, medical interns of the College of Medicine, Jouf University for their contribution in data collection. I extend our sincere thanks to Ahmed Alshaik for his contribution to the questionnaire preparation. Finally, I wish to thank Ashokkumar Thirunavukkarasu in helping the research.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. WHO. Recognizing Neglected Skin Diseases: WHO Publishes Pictorial Training Guide. Available online: https://www.who.int/news/item/08-06-2018-recognizing-neglected-skin-diseases-who-publishes-pictorial-training-guide (accessed on 31 May 2022).
2. Alanazi, T.; Alajroush, W.; Alharthi, R.; Alshalhoub, M.; Alshehri, M. Prevalence of acne vulgaris, its contributing factors, and treatment satisfaction among the saudi population in Riyadh, Saudi Arabia: A cross-sectional study. *J. Dermatol. Dermatol. Surg.* 2020, 24, 33–37. [CrossRef]
3. Tayel, K.; Attia, M.; Agamia, N.; Fadl, N. Acne vulgaris: Prevalence, severity, and impact on quality of life and self-esteem among Egyptian adolescents. *J. Egypt. Public Health Assoc.* 2020, 95, 30. [CrossRef] [PubMed]
4. Yang, Y.C.; Tu, H.P.; Hong, C.H.; Chang, W.C.; Fu, H.C.; Ho, J.C.; Chang, W.P.; Chuang, H.Y.; Lee, C.H. Female gender and acne disease are jointly and independently associated with the risk of major depression and suicide: A national population-based study. *Biomed. Res. Int.* 2014, 2014, 504279. [CrossRef]
5. Alanazi, M.S.; Hammad, S.M.; Mohamed, A.E. Prevalence and psychological impact of Acne vulgaris among female secondary school students in Arar city, Saudi Arabia, in 2018. *Electron. Physician* 2018, 10, 7224–7229. [CrossRef]
6. Oge, L.K.; Broussard, A.; Marshall, M.D. Acne Vulgaris: Diagnosis and Treatment. *Am. Fam. Physician* 2019, 100, 475–484.
7. Bagatin, E.; Costa, C.S. The use of isotretinoin for acne—An update on optimal dosing, surveillance, and adverse effects. *Expert Rev. Clin. Pharmacol.* 2020, 13, 885–897. [CrossRef]
8. Albadr, T.; Alruhaimi, D.; Cahusac, P.; Rohra, D. Knowledge and use of isotretinoin in Saudi female college students: Cross-sectional study. J. Dermatol. Dermatol. Surg. 2019, 23, 76–80. [CrossRef]

9. Bakheet, K.M.A.; Alghanemi, R.G.; Alsiyouni, A.M.; Abduljabbar, M.; Hariri, J. Females’ Knowledge and Use of Isotretinoin (Roaccutane) in the Western Region of Saudi Arabia. Cureus 2020, 12, e12148. [CrossRef]

10. Brzezinski, P.; Borowska, K.; Chiriac, A.; Smigielski, J. Adverse effects of isotretinoin: A large, retrospective review. Dermatol. Ther. 2017, 30, e12483. [CrossRef]

11. Tkachenko, E.; Singer, S.; Sharma, P.; Barbieri, J.; Mostaghimi, A. US Food and Drug Administration Reports of Pregnancy and Pregnancy-Related Adverse Events Associated with Isotretinoin. JAMA Dermatol. 2019, 155, 1175–1179. [CrossRef]

12. Draghici, C.C.; Miulescu, R.G.; Petca, R.C.; Petca, A.; Dumitrascu, M.C.; Sandru, F. Teratogenic effect of isotretinoin in both fertile females and males (Review). Exp. Med. 2021, 21, 534. [CrossRef]

13. Holst, H.; Muhari-Stark, E.; Lava, S.A. Teratogenicity of systemic isotretinoin. Minerva Pediatr. 2018, 70, 107–109. [CrossRef] [PubMed]

14. SFDA. Saudi Food and Drug Authority. Available online: https://www.sfda.gov.sa/en (accessed on 1 June 2022).

15. USFDA. US Food and Drug Administration. Available online: https://www.fda.gov/drug-safety-update/oral-retinoid-medicines-revised-and-simplified-pregnancy-prevention-educational-materials-for-healthcare-professionals-and-women (accessed on 26 October 2022).

16. GOV.UK. Oral Retinoid Medicines: Revised and Simplified Pregnancy Prevention Educational Materials for Healthcare Professionals and Women. Available online: https://www.gov.uk/drug-safety-update/oral-retinoid-medicines-revised-and-simplified-pregnancy-prevention-educational-materials-for-healthcare-professionals-and-women (accessed on 26 October 2022).

17. SFDA. SFDA—Isootretinoin Prescribing Guidleines. Available online: https://www.sfda.gov.sa/sites/default/files/2020-11/Isoretinoin-Prescribing-GuideLines.pdf (accessed on 1 June 2022).

18. Ibrahim, A.A.M.; Alshatri, A.A.; Alsuwaidan, S.; Almutairi, L.; Aljasser, N.; Mahmoud, M.A.; Alaseeri, A.; Almonysir, A.; Alotaibi, B.; Alrasheed, B.; et al. Awareness of isotretinoin use and Saudi FDA pregnancy prevention program in Riyadh, Saudi Arabia: A cross-sectional study among female patients. Saudi Pharm. J. 2021, 29, 527–532. [CrossRef] [PubMed]

19. Bagatin, E.; Costa, C.S.; Rocha, M.; Picosse, F.R.; Kamamoto, C.S.L.; Pirmez, R.; Ianhez, M.; Miot, H.A. Consensus on the use of oral isotretinoin in dermatology—Brazilian Society of Dermatology. Bras Derm. 2020, 95 (Suppl. 1), 19–38. [CrossRef] [PubMed]

20. Pile, H.D.; Sadiq, N.M. Isotretinoin. In StatPearls; StatPearls Publishing: Treasure Island, FL, USA, 2022.

21. Layton, A. The use of isotretinoin in acne. Dermato-Endocrinol. 2009, 1, 162–169. [CrossRef] [PubMed]

22. Molla, A.; Alrizqi, H.; Alruhaili, E.; Alrizqi, S.; Alsubhi, A. Knowledge and use of isotretinoin in Al-Madinah population, Saudi Arabia. Int. J. Med. Dev. Ctries. 2020, 4, 107–112. [CrossRef]

23. Rashid, Z.A.; Al-Tabakha, M.M.; Alomar, M.J. Proper Counseling and Dispensing of Isotretinoin Capsule Products by Community Pharmacists in UAE: A Simulated Patient Study. Clin. Cosmet. Investig. Derm. 2020, 13, 405–414. [CrossRef]

24. Kara Polat, A.; Akin Belli, A.; Ergun, E.Z.; Manav Bas, V.; Erdil, D.; Koku Aksu, A.E.; Gurel, M.S. Knowledge levels and concerns about oral isotretinoin treatment in the parents of adolescent acne patients. Dermatol. Ther. 2020, 33, e13669. [CrossRef]

25. Tugrul Ayanoglu, B.; Demirdag, H.G.; Yalici Armagan, B.; Bezirgan, O. Perceptions about oral isotretinoin treatment. Dermatol. Ther. 2019, 32, e12873. [CrossRef]

26. Younis, N.S.; Al-Harbi, N.Y. Public Understanding and Awareness of Isotretinoin Use and Safety in Al Ahsa, Eastern Saudi Arabia. Innov. Regul. Sci. 2019, 53, 618–622. [CrossRef]

27. Jarab, A.S.; Al-Azzam, S.; Almutairi, S.; Mukattash, T.L. Patients’ Knowledge and Information Needs about Isotretinoin Therapy Use in Jordan. Int. J. Clin. Pract. 2022, 2022, 9443884. [CrossRef] [PubMed]

28. Imam, M.S.; Abdel-Sattar, M.; Alyonah, G.A.; Aiman, R.S.; Aljassim, Y.A. Knowledge and awareness of acne patients about isotretinoin use and safety in dawadmi governorate, riyadh region, Saudi Arabia. Syst. Rev. Pharm. 2021, 12, 2339–2343.

29. Saqib, A.; Atif, M.; Ikram, R.; Riaz, F.; Abubakar, M.; Saeed, S. Factors affecting patients’ knowledge about dispensed medicines: A Qualitative study of healthcare professionals and patients in Pakistan. PLoS ONE 2018, 13, e0197482. [CrossRef] [PubMed]

30. Fagerlin, A.; Sepucha, K.R.; Couper, M.P.; Levin, C.A.; Singer, E.; Zikmund-Fisher, B.J. Patients’ knowledge about 9 common medications: The DECISIONS survey. Med. Decis. Mak. 2010, 30, 355–352. [CrossRef]

31. Al-Harbi, M. Concerns and awareness of acne patients about isotretinoin in qassim region of saudi arabia. Int. J. Health Sci. 2010, 4, 47–51.

32. Almaeen, A.; Wani, F.A.; Thirunavukkarasu, A. Knowledge and attitudes towards stem cells and the significance of their medical application among healthcare sciences students of Jouf University. Peerj 2021, 9, e10661. [CrossRef]